The "Motoric Cognitive Risk" Syndrome in the Canadian Population (MCR-CardioV)

March 28, 2022 updated by: Olivier Beauchet, Jewish General Hospital

The "Motoric Cognitive Risk" Syndrome in the Canadian Population: Analysis of Baseline Assessment of the Canadian Longitudinal Study on Aging (CLSA)

Cognition and locomotion are two human abilities controlled by the brain. Their decline is highly prevalent with aging, and is greater than the simple sum of their respective prevalence, suggesting a complex age-related interplay between cognition and locomotion. Recently, a systematic review and meta-analysis has provided evidence that poor gait performance predicts dementia and, in particular, has demonstrated that "motoric cognitive risk" (MCR) syndrome, which has been described in cognitively healthy individuals and combines subjective cognitive complaint with objective slow gait speed, is a pre-dementia syndrome. The uniqueness of "motoric cognitive risk" (MCR)syndrome is that it does not rely on a complex evaluation or laboratory investigations. Thus, it is easy to apply in population-based settings. The overall objective of the proposal is to examine the epidemiology of the newly reported "motoric cognitive risk" (MCR) syndrome, in the Quebec population using the database of the NuAge study.

Study Overview

Study Type

Observational

Enrollment (Anticipated)

1461

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Quebec
      • Montréal, Quebec, Canada, H3T 1E2
        • Jewish General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

45 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Individuals eligible for this study will be participants of the comprehensive Canadian Longitudinal Study on Aging (n=30,097). They are separated in four age groups (i.e.; 45-54, 54-64, 65-74 and 75-85). Each group will be divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases.

Description

Inclusion Criteria:

  • Individuals eligible for this study will be participants of the NuAge study

Exclusion Criteria:

  • Individuals not eligible for the NuAge study
  • dementia
  • mobility disability
  • no information about cognitive complaint
  • no measure of walking speed

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
CVRF
individuals with cardio-vascular risk factors and diseases
Participants' baseline characteristics will be summarized using means and standard deviations or frequencies and percentages, as appropriate.
WCVRF
individuals without cardio-vascular risk factors and diseases
Participants' baseline characteristics will be summarized using means and standard deviations or frequencies and percentages, as appropriate.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cardio-vascular risk factors and diseases assessed using reported health condition
Time Frame: 1 day
medical history
1 day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cardio-vascular risk factors and diseases assessed using physical examination: BMI
Time Frame: 1 day
body mass index
1 day
Cardio-vascular risk factors and diseases assessed using physical examination: HW ratio
Time Frame: 1 day
hip-waist ratio
1 day
Cardio-vascular risk factors and diseases assessed using physical examination: blood pressure
Time Frame: 1 day
(value of systolic, diastolic when participants are seated in an upright position in a chair)
1 day
Disability and functional limitations
Time Frame: 1 day
Disability and functional limitations : ADL (activities of daily life)
1 day
Disability and functional limitations
Time Frame: 1 day
Disability and functional limitations : IADL (instrumental activities of daily life)
1 day
Disability and functional limitations
Time Frame: 12 months
History of falls during the past 12 months
12 months
Depression
Time Frame: 1 day
measured by the 10 items of the Center for Epidemiological Studies Short Depression Scale. Participants with a score of 10 or greater are considered as depressed. Scores with more than 2 missing items will be excluded.
1 day
Cognitive performance
Time Frame: 1 day
Prospective Memory Test (PMT)
1 day
Cognitive performance
Time Frame: 1 day
Stroop Neurological Screening Test
1 day
Cognitive performance
Time Frame: 1 day
Controlled Oral Word Association Test (FAS)
1 day
Cognitive performance
Time Frame: 1 day
Choice Reaction Time Test (CRT)
1 day
physical and mental health
Time Frame: 1 day
Number of drugs daily taken
1 day
physical and mental health
Time Frame: 1 day
Self-perception of health and mental health
1 day
Physical performance
Time Frame: 1 day
Muscle strength estimated using the handgrip strength
1 day
Physical performance
Time Frame: 1 day
five-time sit-to-stand test
1 day
Physical performance
Time Frame: 1 day
Physical Activity Scale for the Elderly, scored between 0 and 400, low scores indicate sarcopenia
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 22, 2017

Primary Completion (Actual)

August 21, 2021

Study Completion (Anticipated)

December 21, 2022

Study Registration Dates

First Submitted

August 21, 2018

First Submitted That Met QC Criteria

September 18, 2018

First Posted (Actual)

September 20, 2018

Study Record Updates

Last Update Posted (Actual)

March 29, 2022

Last Update Submitted That Met QC Criteria

March 28, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • CODIM-FLP-16 261

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Diseases

Clinical Trials on Summarize of participants' characteristics using means and standard deviations or frequencies and percentages

Subscribe